France· FR:61186021
RIVAROXABAN VIATRIS 20 mg, comprimé pelliculé
A medicinal product containing rivaroxaban, registered in France by VIATRIS (IRLANDE), on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- RIVAROXABAN
- Manufacturer
- VIATRIS (IRLANDE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 3
2 priced- cip133400930276211plaquettes PVC PVDC aluminium de 28 comprimés (calendaire)EUR 12.37
- cip1334009303015171 flacon(s) polyéthylène haute densité (PEHD) de 30 comprimé(s)EUR 13.25
- cip133400955094142100 plaquettes PVC PVDC aluminium de 1 comprimé (dose unitaire)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Rivaroxaban in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaAXALTRA+pharma arzneimittel gmbh, Graz
- SpainBLOMENSY 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGEgis Pharmaceuticals Plc.
- PolandAxaltrapharma arzneimittel gmbh
- SwitzerlandRivarax 20 mg, FilmtablettenDrossapharm AG
- NetherlandsBlomensy 20 mg filmomhulde tablettenEgis Pharmaceuticals Plc
- SwedenBevimlar 20 mg Filmdragerad tablettSTADA Arzneimittel AG
- FinlandDovequaBausch Health Ireland Limited
- IrelandRivaroxaban 20 mg film-coated tabletsRenata Pharmaceuticals (Ireland) Limited
Authorised across Europe · EMA
The same active substance is authorised in 30 EEA countries. Names it is sold under:
- Austria · Rivahib, Rivaroksaban Grindeks
- Belgium · Rivaroxaban, Rivaroxaban Eg
- Bulgaria · Xaboplax Sandoz Pharmaceuticals D.D, Виатрикс
- Cyprus · Enkia, Naxat
- Czechia · Axaltra, Bevimlar
- Germany · Elmardya, Rivadia
- Denmark · Blomensy, Dovequa
- Estonia · Enkia, Kardatuxan
- Spain · Blomensy, Elmardya
- Finland · Blomensy, Dovequa
- United Kingdom (Northern Ireland) · Rivaroxaban, Rivaroxaban Abdi
- Greece · Blomensy, Cinstel
- Croatia · Aban, Bevimlar
- Hungary · Dovequa, Evoxyr
- Ireland · Rivaroxaban Ascend, Rivaroxaban Azure
- Iceland · Agublon, Barsovi
- Italy · Ellebax, Indifaxa
- Liechtenstein · Rivaroxaban Accord, Rivaroxaban Viatris
- Lithuania · Enkia, Kardatuxan
- Luxembourg · Rivaroxaban Eg, Rivaroxaban Eg (Eurogenerics) Nv
- Latvia · Kardatuxan, Mibrex
- Malta · Enkia, Naxat
- Netherlands · Blomensy, Rivaroksaban Grindeks
- Norway · Dovequa, Rivaroxaban Accord
- Poland · Axaltra, Bevimlar
- Portugal · Closderive, Enkia
- Romania · Closderive, Enkia
- Sweden · Bevimlar, Blomensy
- Slovenia · Dovequa, Ribas
- Slovakia · Assubex, Bevimlar
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cd8b3718-fba0-4da6-827b-0c0193876c06 GET /v1/drugs/cd8b3718-fba0-4da6-827b-0c0193876c06?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "61186021",
"date_amm": "2021-11-12",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/21/1588",
"substance": "RIVAROXABAN",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé pelliculé",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about rivaroxaban.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.